24 Nov 2020

Merck agrees to buy biopharma firm OncoImmune for $425m

Merck (MSD) has signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash. Under the…

23 Nov 2020

Mesoblast signs ARDS therapy development deal with Novartis

Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell (MSC) product remestemcel-L. Remestemcel-L is an investigational therapy with culture-expanded…

18 Nov 2020

BMS acquires biopharma firm MyoKardia for $13.1bn

Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn. Last month, BMS signed a definitive merger agreement to purchase all…